Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

106.49
-1.3000-1.21%
Pre-market: 106.48-0.0100-0.01%05:04 EDT
Volume:1.01M
Turnover:108.82M
Market Cap:9.39B
PE:-52.98
High:110.00
Open:108.85
Low:105.71
Close:107.79
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:1.19
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:9.83
PE(LYR):-53.91

Loading ...

Spyre Therapeutics CEO Cameron Turtle Sells Common Shares Worth $1.32 Million

Reuters
·
Jul 03

Spyre Therapeutics Grants Inducement Equity Awards of 58,843 Stock Options, 2,134 Rsus to New Hires

Reuters
·
Jul 03

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Jul 03

Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative

Simply Wall St.
·
Jul 02

Spyre Therapeutics CFO Scott Burrows Disposes of Common Shares Worth $1.31 Million

Reuters
·
Jun 27

Spyre Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 27

Spyre Therapeutics Files for Mixed Shelf; Size not Disclosed - Filing

THOMSON REUTERS
·
Jun 27

Movement Alert|Spyre Therapeutics Falls 5.04% in Pre-Market Trading, Director Share Sale Continues to Pressure Stock

Market Focus
·
Jun 25

Spyre Therapeutics Shares Fall After Director Sells $2 Million in Stock

MT Newswires Live
·
Jun 25

Movement Alert|Spyre Therapeutics Falls 14.76% in Regular Trading, Trading at $85.98

Market Focus
·
Jun 24

Movement Alert|SPYRE THERAPEUTICS Falls 10.83% in Pre-Market Trading, Trading at $86.54

Market Focus
·
Jun 24

Spyre Therapeutics director Michael Thomas Henderson disposes of 20,000 common shares for $2 million

Reuters
·
Jun 24

Movement Alert|SPYRE THERAPEUTICS Overnight Decline 7.91%, Trading at $89.37

Market Focus
·
Jun 24

Movement Alert|Spyre Therapeutics Rises 8.19% in After-Hours Trading, Trading at $105.0

Market Focus
·
Jun 24

Spyre Therapeutics : Deutsche Bank Raises Target Price to $135 From $115

THOMSON REUTERS
·
Jun 23

Spyre Therapeutics (SYRE) Is Up 16.5% After Strong Phase 2 SKYLINE Data in Ulcerative Colitis

Simply Wall St.
·
Jun 18

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)

TIPRANKS
·
Jun 16

Spyre says bowel disease drug cuts inflammation in mid-stage trial

Reuters
·
Jun 15

Spyre Therapeutics announces SKYLINE trial achieves primary endpoint

TIPRANKS
·
Jun 15

Spyre says SPY002 hits primary endpoint in Phase 2 SKYLINE ulcerative colitis trial Part A induction data

Reuters
·
Jun 15